Case Activity (737)

1. Filed: October 05, 2026 | Entered: October 05, 2026 Epic Reference Labs, Inc. et al v. Cigna Health and Life Insurance Company et al

   110 Insurance | Connecticut

   Memorandum in Opposition re 232 MOTION to Set Aside Pursuant to Rules 60(b), 26(g), 26(e), & 37(b)(2) filed by Cigna Health and Life Insurance Company. (Attachments: # 1 Index of Exhibits, # 2 Exhibit 1 - CIGNA19-1326 0004741-744 (Joint Trial Exhibit 148), # 3 Exhibit 2 - CIGNA19-1326 0004737-740 (Joint Trial Exhibit 160A), # 4 Exhibit 3 - Declaration of Edward T. Kang in Support of Cigna's Opposition to the Labs' Motion for Relief from Judgment, # 5 Exhibit 4 - Michael Ligotti Deposition Designations, # 6 Exhibit 5 - CIGNA19-1326 0289454-CIGNA19-1326 0289454.002, # 7 Exhibit 6 - CIGNA19-1326 0290565 (Welch Deposition Exhibit 2), # 8 Exhibit 7 - CIGNA19-1326 0292368, # 9 Exhibit 8 - CIGNA19-1326 0292369-370, # 10 Exhibit 9 - CIGNA19-1326 0292131, # 11 Exhibit 10 - CIGNA19-1326 0004558, # 12 Exhibit 11 - CIGNA19-1326 0289878-883, # 13 Exhibit 12a and 12b - CIGNA19-1326 0290074, # 14 Exhibit 13 - September 13, 2022 Transmittal email and letter regarding Production Volume 21, # 15 Exhibit 14 - CIGNA19-1326 0291664-664_0001 (Welch Deposition Exhibit 12), # 16 Exhibit 15a and 15b - CIGNA19-1326 0291388, # 17 Exhibit 16a and 16b - CIGNA19-1326 0291384, # 18 Exhibit 17a and 17b - CIGNA19-1326 0291386, # 19 Exhibit 18 - CIGNA19-1326 0291599, # 20 Exhibit 19 - December 23, 2021 Transmittal email and letter regarding Production Volume 1, # 21 Exhibit 20 - Michael Goldfarb February 16, 2023 Deposition Transcript Excerpt, # 22 Exhibit 21a and 21b - CIGNA19-1326 0325965-966)(Kang, Edward) (Entered: 10/05/2026)

2. Filed: October 05, 2026 | Entered: October 05, 2026 Cigna Health and Life Insurance Company v. BioHealth Laboratories, Inc. et al

   370 Other Fraud | Connecticut

   Memorandum in Opposition re 588 MOTION to Set Aside Judgment Rules 60(b), 26(g), 26(e), & 37(b)(2) filed by Cigna Health and Life Insurance Company. (Attachments: # 1 Index of Exhibits, # 2 Exhibit 1 - CIGNA19-1326 0004741-744 (Joint Trial Exhibit 148), # 3 Exhibit 2 - CIGNA19-1326 0004737-740 (Joint Trial Exhibit 160A), # 4 Exhibit 3 - Declaration of Edward T. Kang in Support of Cigna's Opposition to the Labs' Motion for Relief from Judgment, # 5 Exhibit 4 - Michael Ligotti Deposition Designations, # 6 Exhibit 5 - CIGNA19-1326 0289454-CIGNA19-1326 0289454.002, # 7 Exhibit 6 - CIGNA19-1326 0290565 (Welch Deposition Exhibit 2), # 8 Exhibit 7 - CIGNA19-1326 0292368, # 9 Exhibit 8 - CIGNA19-1326 0292369-370, # 10 Exhibit 9 - CIGNA19-1326 0292131, # 11 Exhibit 10 - CIGNA19-1326 0004558, # 12 Exhibit 11 - CIGNA19-1326 0289878-883, # 13 Exhibit 12a and 12b - CIGNA19-1326 0290074, # 14 Exhibit 13 - September 13, 2022 Transmittal email and letter regarding Production Volume 21, # 15 Exhibit 14 - CIGNA19-1326 0291664-664_0001 (Welch Deposition Exhibit 12), # 16 Exhibit 15a and 15b - CIGNA19-1326 0291388, # 17 Exhibit 16a and 16b - CIGNA19-1326 0291384, # 18 Exhibit 17a and 17b - CIGNA19-1326 0291386, # 19 Exhibit 18 - CIGNA19-1326 0291599, # 20 Exhibit 19 - December 23, 2021 Transmittal email and letter regarding Production Volume 1, # 21 Exhibit 20 - Michael Goldfarb February 16, 2023 Deposition Transcript Excerpt, # 22 Exhibit 21a and 21b - CIGNA19-1326 0325965-966)(Kang, Edward) (Entered: 10/05/2026)

3. 735 additional result(s)